Interferon-gamma signaling inhibition ameliorates angiotensin II-induced cardiac damage


  • L. Marko
  • H. Kvakan
  • J.K. Park
  • F. Qadri
  • B. Spallek
  • K.J. Binger
  • E.P. Bowman
  • M. Kleinewietfeld
  • V. Fokuhl
  • R. Dechend
  • D.N. Mueller


  • Hypertension


  • Hypertension 60 (6): 1430-1436


  • Angiotensin (Ang) II induces vascular injury in part by activating innate and adaptive immunity; however, the mechanisms are unclear. We investigated the role of interferon (IFN)-{gamma} and interleukin (IL)-23 signaling. We infused Ang II into IFN-{gamma} receptor (IFN-{gamma}R) knockout mice and wild-type controls, as well as into mice treated with neutralizing antibodies against IL-23 receptor and IL-17A. Ang II-treated IFN-{gamma}R knockout mice exhibited reduced cardiac hypertrophy, reduced cardiac macrophage and T-cell infiltration, less fibrosis, and less arrhythmogenic electric remodeling independent of blood pressure changes. In contrast, IL-23 receptor antibody treatment did not reduce cardiac hypertrophy, fibrosis, or electric remodeling despite mildly reduced inflammation. IL-17A antibody treatment behaved similarly. In the kidney, IFN-{gamma}R deficiency reduced inflammation and tubulointerstitial damage and improved glomerular filtration rate. Nonetheless, albuminuria was increased compared with Ang II-treated wild-type controls. The glomeruli of Ang II-treated IFN-{gamma}R knockout mice exhibited fewer podocytes, less nephrin and synaptopodin staining, and impaired podocyte autophagy. Thus, IFN-{gamma} blockade, but not IL-23 receptor antibody treatment, protects from Ang II-induced cardiac damage and electric remodeling. In the kidney, IFN-{gamma} signaling acts in a cell type-specific manner. Glomerular filtration rate is preserved in the absence of the IFN-{gamma}R, whereas podocytes may require the IFN-{gamma}R in the presence of Ang II for normal integrity and function.